NEW YORK – The US Food and Drug Administration on Friday approved Daiichi Sankyo and AstraZeneca's antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu) for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer who have previously received a trastuzumab (Genentech's Herceptin)-based treatment.